AnaptysBio Common Stock vs Short Long Term Debt Total Analysis

ANAB Stock

USD 25.07 0.40 1.57%

AnaptysBio financial indicator trend analysis is way more than just evaluating AnaptysBio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AnaptysBio is a good investment. Please check the relationship between AnaptysBio Common Stock and its Short Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.

Common Stock vs Short Long Term Debt Total

Common Stock vs Short Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AnaptysBio Common Stock account and Short Long Term Debt Total. At this time, the significance of the direction appears to have weak relationship.

The correlation between AnaptysBio's Common Stock and Short Long Term Debt Total is 0.3. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of AnaptysBio, assuming nothing else is changed. The correlation between historical values of AnaptysBio's Common Stock and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of AnaptysBio are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Common Stock i.e., AnaptysBio's Common Stock and Short Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Common Stock

Short Long Term Debt Total

Most indicators from AnaptysBio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AnaptysBio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.At present, AnaptysBio's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.57, whereas Tax Provision is forecasted to decline to (4.2 K).

	2021	2022	2023	2024 (projected)
Interest Expense	1.5M	21.1M	18.1M	19.0M
Depreciation And Amortization	468K	7.6M	2.4M	2.8M

Interest Expense Depreciation And Amortization

AnaptysBio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets
Total Assets		0.66	0.56	0.82	0.82	0.69	0.8	-0.64	-0.72	0.5	0.66	0.86	-0.18	0.99	0.79	-0.46	0.62	0.75	0.78	0.65	0.64	0.99	0.45	0.79	0.66	0.93
Short Long Term Debt Total	0.66		0.52	0.49	0.28	0.76	0.49	-0.32	-0.58	0.0	0.37	0.72	0.05	0.61	0.35	-0.52	0.75	0.6	0.57	0.74	0.72	0.62	0.26	0.3	0.57	0.64
Other Current Liab	0.56	0.52		0.64	0.08	0.85	0.53	-0.11	-0.96	0.11	0.14	0.44	-0.23	0.56	0.53	-0.28	0.9	0.79	0.91	0.91	0.91	0.57	-0.09	0.46	0.97	0.78
Total Current Liabilities	0.82	0.49	0.64		0.59	0.57	0.87	-0.27	-0.8	0.68	0.3	0.63	-0.11	0.82	0.77	-0.51	0.59	0.8	0.71	0.62	0.6	0.83	0.32	0.7	0.63	0.85
Total Stockholder Equity	0.82	0.28	0.08	0.59		0.17	0.64	-0.67	-0.27	0.6	0.68	0.64	-0.06	0.84	0.62	-0.41	0.08	0.43	0.39	0.11	0.11	0.83	0.6	0.68	0.2	0.64
Property Plant And Equipment Net	0.69	0.76	0.85	0.57	0.17		0.54	-0.35	-0.87	0.06	0.39	0.67	-0.26	0.66	0.55	-0.24	0.98	0.73	0.87	0.98	0.98	0.67	-0.01	0.52	0.89	0.8
Current Deferred Revenue	0.8	0.49	0.53	0.87	0.64	0.54		-0.51	-0.66	0.52	0.53	0.59	-0.12	0.82	0.71	-0.63	0.51	0.65	0.69	0.54	0.52	0.82	0.18	0.68	0.59	0.76
Net Debt	-0.64	-0.32	-0.11	-0.27	-0.67	-0.35	-0.51		0.2	-0.26	-1.0	-0.36	-0.01	-0.68	-0.39	0.27	-0.19	-0.21	-0.46	-0.19	-0.26	-0.68	-0.06	-0.44	-0.3	-0.46
Retained Earnings	-0.72	-0.58	-0.96	-0.8	-0.27	-0.87	-0.66	0.2		-0.35	-0.24	-0.58	0.21	-0.71	-0.66	0.33	-0.91	-0.88	-0.92	-0.93	-0.92	-0.72	-0.07	-0.6	-0.94	-0.89
Accounts Payable	0.5	0.0	0.11	0.68	0.6	0.06	0.52	-0.26	-0.35		0.25	0.31	0.24	0.52	0.41	-0.33	0.05	0.4	0.23	0.09	0.08	0.52	0.26	0.41	0.09	0.46
Cash	0.66	0.37	0.14	0.3	0.68	0.39	0.53	-1.0	-0.24	0.25		0.4	0.01	0.71	0.4	-0.29	0.24	0.24	0.49	0.24	0.3	0.7	0.07	0.45	0.33	0.5
Non Current Assets Total	0.86	0.72	0.44	0.63	0.64	0.67	0.59	-0.36	-0.58	0.31	0.4		-0.23	0.8	0.65	-0.35	0.62	0.57	0.61	0.63	0.59	0.8	0.48	0.68	0.52	0.76
Non Currrent Assets Other	-0.18	0.05	-0.23	-0.11	-0.06	-0.26	-0.12	-0.01	0.21	0.24	0.01	-0.23		-0.16	-0.64	-0.41	-0.23	-0.19	-0.23	-0.23	-0.26	-0.16	-0.31	-0.66	-0.25	-0.27
Cash And Short Term Investments	0.99	0.61	0.56	0.82	0.84	0.66	0.82	-0.68	-0.71	0.52	0.71	0.8	-0.16		0.79	-0.46	0.59	0.75	0.79	0.62	0.62	1.0	0.42	0.79	0.66	0.93
Common Stock Total Equity	0.79	0.35	0.53	0.77	0.62	0.55	0.71	-0.39	-0.66	0.41	0.4	0.65	-0.64	0.79		-0.04	0.51	0.64	0.67	0.53	0.54	0.79	0.44	0.98	0.59	0.8
Common Stock Shares Outstanding	-0.46	-0.52	-0.28	-0.51	-0.41	-0.24	-0.63	0.27	0.33	-0.33	-0.29	-0.35	-0.41	-0.46	-0.04		-0.26	-0.45	-0.32	-0.29	-0.25	-0.47	-0.21	-0.03	-0.27	-0.43
Non Current Liabilities Total	0.62	0.75	0.9	0.59	0.08	0.98	0.51	-0.19	-0.91	0.05	0.24	0.62	-0.23	0.59	0.51	-0.26		0.76	0.86	1.0	0.99	0.6	-0.02	0.46	0.9	0.78
Other Current Assets	0.75	0.6	0.79	0.8	0.43	0.73	0.65	-0.21	-0.88	0.4	0.24	0.57	-0.19	0.75	0.64	-0.45	0.76		0.76	0.79	0.79	0.76	0.42	0.59	0.75	0.91
Other Stockholder Equity	0.78	0.57	0.91	0.71	0.39	0.87	0.69	-0.46	-0.92	0.23	0.49	0.61	-0.23	0.79	0.67	-0.32	0.86	0.76		0.87	0.87	0.79	-0.03	0.65	0.97	0.88
Total Liab	0.65	0.74	0.91	0.62	0.11	0.98	0.54	-0.19	-0.93	0.09	0.24	0.63	-0.23	0.62	0.53	-0.29	1.0	0.79	0.87		0.99	0.62	0.01	0.48	0.91	0.81
Property Plant And Equipment Gross	0.64	0.72	0.91	0.6	0.11	0.98	0.52	-0.26	-0.92	0.08	0.3	0.59	-0.26	0.62	0.54	-0.25	0.99	0.79	0.87	0.99		0.63	0.0	0.49	0.91	0.81
Total Current Assets	0.99	0.62	0.57	0.83	0.83	0.67	0.82	-0.68	-0.72	0.52	0.7	0.8	-0.16	1.0	0.79	-0.47	0.6	0.76	0.79	0.62	0.63		0.42	0.79	0.67	0.93
Short Term Debt	0.45	0.26	-0.09	0.32	0.6	-0.01	0.18	-0.06	-0.07	0.26	0.07	0.48	-0.31	0.42	0.44	-0.21	-0.02	0.42	-0.03	0.01	0.0	0.42		0.47	-0.09	0.41
Common Stock	0.79	0.3	0.46	0.7	0.68	0.52	0.68	-0.44	-0.6	0.41	0.45	0.68	-0.66	0.79	0.98	-0.03	0.46	0.59	0.65	0.48	0.49	0.79	0.47		0.55	0.79
Other Liab	0.66	0.57	0.97	0.63	0.2	0.89	0.59	-0.3	-0.94	0.09	0.33	0.52	-0.25	0.66	0.59	-0.27	0.9	0.75	0.97	0.91	0.91	0.67	-0.09	0.55		0.81
Net Tangible Assets	0.93	0.64	0.78	0.85	0.64	0.8	0.76	-0.46	-0.89	0.46	0.5	0.76	-0.27	0.93	0.8	-0.43	0.78	0.91	0.88	0.81	0.81	0.93	0.41	0.79	0.81

Click cells to compare fundamentals

AnaptysBio Account Relationship Matchups

AnaptysBio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	435.2M	416.6M	643.1M	610.4M	452.4M	354.3M
Short Long Term Debt Total	2.2M	342K	21.0M	19.5M	17.8M	10.8M
Other Current Liab	871K	15.3M	12.9M	21.6M	31.0M	32.5M
Total Current Liabilities	29.5M	19.8M	16.1M	26.1M	37.4M	19.3M
Total Stockholder Equity	405.0M	396.7M	356.4M	262.1M	88.1M	83.7M
Property Plant And Equipment Net	1.6M	1.8M	21.8M	20.0M	18.3M	19.2M
Net Debt	(168.8M)	(250.1M)	(474.8M)	(51.9M)	(18.2M)	(19.1M)
Retained Earnings	(244.0M)	(264.0M)	(321.8M)	(450.5M)	(614.1M)	(583.4M)
Accounts Payable	16.2M	4.2M	1.7M	2.8M	4.7M	4.2M
Cash	171.0M	250.5M	495.7M	71.3M	36.0M	34.2M
Non Current Assets Total	57.5M	20.0M	89.2M	163.2M	45.6M	53.5M
Non Currrent Assets Other	208K	1.5M	662K	256K	230.4K	218.9K
Cash And Short Term Investments	374.2M	393.7M	548.1M	441.2M	390.9M	295.2M
Common Stock Shares Outstanding	27.1M	27.3M	27.4M	28.2M	26.9M	21.0M
Liabilities And Stockholders Equity	435.2M	416.6M	643.1M	610.4M	452.4M	354.3M
Non Current Liabilities Total	654K	4.6M	270.5M	322.2M	326.8M	343.2M
Other Current Assets	3.5M	2.9M	4.9M	4.5M	9.1M	9.5M
Other Stockholder Equity	213.5M	660.7M	678.6M	717.8M	703.0M	738.1M
Total Liab	30.2M	19.8M	286.6M	348.3M	364.3M	382.5M
Property Plant And Equipment Gross	1.6M	1.8M	21.8M	20.0M	24.5M	25.7M
Total Current Assets	377.7M	396.6M	553.9M	447.2M	406.8M	300.8M
Accumulated Other Comprehensive Income	338K	(4K)	(422K)	(5.2M)	(797K)	(836.9K)
Short Term Debt	2.2M	342K	1.5M	1.6M	1.8M	2.3M
Other Liab	796K	654K	251.1M	304.4M	350.1M	367.6M
Net Tangible Assets	405.0M	396.7M	627.0M	584.3M	672.0M	705.6M
Other Assets	208K	139K	18.2M	256K	294.4K	279.7K
Property Plant Equipment	3.0M	1.8M	2.3M	2.1M	2.4M	1.6M
Capital Surpluse	648.7M	660.7M	678.6M	717.8M	825.5M	517.6M
Retained Earnings Total Equity	(244.0M)	(264.0M)	(321.8M)	(450.5M)	(405.4M)	(385.2M)
Short Term Investments	203.2M	143.2M	52.4M	369.9M	354.9M	252.1M
Capital Lease Obligations	871K	342K	21.0M	19.5M	17.8M	9.4M
Net Invested Capital	406.4M	396.7M	356.4M	262.1M	88.1M	83.7M
Long Term Investments	54.3M	17.5M	67.1M	142.9M	27.0M	25.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
GOOG	Alphabet Inc Class C
C	Citigroup

When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:

How To Invest In AnaptysBio

Details

Is AnaptysBio Stock a good investment?

Details

What is AnaptysBio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.

Note that the AnaptysBio information on this page should be used as a complementary analysis to other AnaptysBio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Complementary Tools for AnaptysBio Stock analysis

When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.

	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Transaction History View history of all your transactions and understand their impact on performance

Is AnaptysBio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.14)

Revenue Per Share

0.862

Quarterly Revenue Growth

4.225

Return On Assets

(0.20)

Return On Equity

(1.37)

The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AnaptysBio Common Stock vs Short Long Term Debt Total Analysis

Common Stock vs Short Long Term Debt Total

Common Stock vs Short Long Term Debt Total Correlation Analysis

Correlation Coefficient

Common Stock

Short Long Term Debt Total

AnaptysBio fundamental ratios Correlations

AnaptysBio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AnaptysBio fundamental ratios Accounts

Also Currently Popular

Complementary Tools for AnaptysBio Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 0.99	Total Liab

Cash	- 1.0	Net Debt
Retained Earnings	- 0.96	Other Current Liab
Other Liab	- 0.94	Retained Earnings
Total Liab	- 0.93	Retained Earnings
Property Plant And Equipment Gross	- 0.92	Retained Earnings
Other Stockholder Equity	- 0.92	Retained Earnings